Point-of-Care Influenza Testing in the Pediatric Emergency Department

Pediatr Emerg Care. 2020 Nov;36(11):515-518. doi: 10.1097/PEC.0000000000002250.

Abstract

Objectives: To see what the impact of introducing a rapid polymerase chain reaction-based influenza test has on length of stay (LOS) in emergency department, use of imaging, serum or urine testing, antibiotic use, and antiviral use.

Methods: Audit of electronic medical health records was performed for all emergency department visits from 2014 to 2018 between November and March, which was defined as peak flu season. Patients were included if they were between 3 months and 18 years of age, presented during peak flu season, and were tested for influenza. The pre-point of care (POC) period was defined as November through March of 2014 to 2017 which was compared with the post-POC group which was defined as November through March of 2017 to 2018.

Results: Patients tested for influenza in the pre-POC period were more likely to have complete blood count testing (44.7% vs 25.6% P < 0.01), more likely to have blood cultures performed (30% vs 16.3%, P < 0.01), more likely to have urine testing performed (21.5% vs 12.2%, P < 0.01), and more likely to have a chest radiograph completed (47.5% vs 34.4%, P < 0.01). There was no significant difference in rates of antibiotics used. There was increased rates of oseltamivir used in the post-POC period (21.2% vs 13.3%, P < 0.05. The median LOS decreased from 239 minutes in the pre-POC period to 232 minutes in the post-POC period (P < 0.05).

Conclusions: With the introduction of a polymerase chain reaction-based point-of-care influenza test, there were overall decreased rates of invasive blood work, urine studies, and imaging, and median LOS. There was also increased antiviral administration.

MeSH terms

  • Adolescent
  • Anti-Bacterial Agents / therapeutic use
  • Antiviral Agents / therapeutic use
  • Blood Cell Count / statistics & numerical data
  • Child
  • Child, Preschool
  • Diagnostic Imaging / statistics & numerical data
  • Emergency Service, Hospital*
  • Female
  • Hospitals, Pediatric
  • Humans
  • Infant
  • Influenza, Human / diagnosis*
  • Influenza, Human / drug therapy
  • Male
  • Oseltamivir / therapeutic use
  • Point-of-Care Testing*
  • Polymerase Chain Reaction / statistics & numerical data*
  • Retrospective Studies
  • Urinalysis / statistics & numerical data

Substances

  • Anti-Bacterial Agents
  • Antiviral Agents
  • Oseltamivir